Paìno and colleagues, in fact, highlighted the synergistic anticancer effects of PIM447 on a panel of different myeloma cell lines and observed a marked decrease in the phosphorylation of c-Myc at S62 and a downregulation of MYC mRNA levels [216]. Here, MYC is linked to plasma cell myeloma.